TFE3 and renal cell carcinoma: We therefore tested the Mithramycin A analog with lowest reported toxicity, EC-8042 (EntreChem SL) [34], for its activity on TFE3-fusion RCC cells, and demonstrated an EC50 of 26-951nM paired with a minimum viability of ~ 10–65% (Supplementary Figure S2; Supplementary Figure S6E).